El dato que podría predecir el éxito del tratamiento contra el cáncer
Un estudio que incluyó a casi 4,900 pacientes con cáncer de próstata metastásico encontró que los pacientes cuyo nivel de PSA bajó por debajo de 0.2 dentro de nueve meses tenían un 54% menos de…
Valoración
A large study of nearly 4,900 metastatic prostate cancer patients found that those whose PSA levels dropped below 0.2 within nine months had a 54 percent lower risk of death. The researchers caution that the rate of decline alone is not always sufficient to gauge treatment success. This suggests that while early PSA suppression is a strong prognostic signal, clinicians will need to integrate it with other factors. The finding could reshape how treatment efficacy is measured in advanced prostate cancer.